Skip to main content
SpringerLink
Log in

Efficacy of Interferon Treatment for Chronic Hepatitis C Predicted by Feature Subset Selection and Support Vector Machine

  • Original Paper
  • Published:
Journal of Medical Systems Aims and scope Submit manuscript

Abstract

Chronic hepatitis C is a disease that is difficult to treat. At present, interferon might be the only drug, which can cure this kind of disease, but its efficacy is limited and patients face the risk of side effects and high expense, so doctors considering interferon must make a serious choice. The purpose of this study is to establish a simple model and use the clinical data to predict the interferon efficacy. This model is a combination of Feature Subset Selection and the Classifier using a Support Vector Machine (SVM). The study indicates that when five features have been selected, the identification by the SVM is as follows: the identification rate for the effective group is 85%, and the ineffective group 83%. Analysis of selected features show that HCV-RNA level, hepatobiopsy, HCV genotype, ALP and CHE are the most significant features. The results thus serve for the doctors’ reference when they make decisions regarding interferon treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hoofnagle, J. H., Mullen, K. D., Jones, D. B., and Rustgi, V., Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 315:1575–1578, 1986.

    Article  Google Scholar 

  2. Davis, G. L., Balart, L. A., Schiff, E. R., and Lindsay, K., Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N. Engl. J. Med. 321:1501–1506, 1989.

    Article  Google Scholar 

  3. Di Bisceglie, A. M., Martin, P., Kassianides, C., and Lisker-Melman, M., Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 321:1506–1510, 1989.

    Article  Google Scholar 

  4. Hagiwara, H., Hayashi, N., Mita, E., and Ueda, K., Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon—alpha. Hepatology. 15:37–41, 1992.

    Article  Google Scholar 

  5. Lai, M. Y., Kao, J. H., Yang, P. M., Wang, J. T., Chen, P. J., Chan, K. W, Chu, J. S., and Chen, D. S., Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 111:1307–1312, 1996.

    Article  Google Scholar 

  6. Reichard, O., Norkrans, G., Fryden, A., Braconier, J. H., Sonnerborg, A., and Weiland O. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet. 351:83–87, 1998.

    Article  Google Scholar 

  7. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M, Reindollar, R., Goodman, Z. D., Koury, K., Ling, M. H., and Albrecht, J. K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:958–965, 2001.

    Article  Google Scholar 

  8. Fried, M. W., Schiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Hãussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., and Yu, J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975–982, 2002.

    Article  Google Scholar 

  9. Duda, R. O., Hart, P. E & Stork, D. G. Pattern Classification (2nd ed.). Wiley Interscience. New York, NY, 2000.

  10. Cristianini, N., and Shawe-Taylor, J. An Introduction to Support Vector Machines (and other kernel-based learning methods). Cambridge University Press. 2000.

    Google Scholar 

  11. EASL Intemational Consensus Conference on hepatitis C. Paris, 26-28, February 1999 Consensus statement. Journal of Hepatology. 30(5): 956–961, 1999.

    Google Scholar 

  12. Kiyosawa, K., Sodeyama, T., Tanaka, E., and Gibo, Y. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 12:671–675, 1990.

    Article  Google Scholar 

  13. Tong, M. J., el-Farra, N. S., Reikes, A. R., and Co, R. L. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 332:1463–1466, 1995.

    Article  Google Scholar 

  14. Kanai, K., Kako, M., Aikawa, T., and Kumada, T. Clearance of serum hepatitis C virus RNA after interferon therapy in relation to virus genotype. Liver. 15:185–188, 1995.

    Google Scholar 

  15. Kiyosawa, K. The value of hepatitis C virus genotyping to epidemiological and clinical studies. J. Gastroenterol. Hepatol. 12:623–624, 1997.

    Google Scholar 

  16. Chayama, K., Tsubota, A., Kobayashi, M., and Okamoto, K. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology. 25:745–749, 1997.

    Article  Google Scholar 

  17. Kanai, K., Kako, M., and Okamoto, H., HCV genotypes in chronic hepatitis C and response to interferon. Lancet. 339:1543, 1992.

    Article  Google Scholar 

  18. Yoshioka, K., Kakumu, S., Wakita, T., and Ishikawa, T. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: relationship to genotypes of hepatitis C virus. Hepatology. 16:293–299, 1992.

    Article  Google Scholar 

  19. Nousbaum, J. B., Pol, S., Naloas, B., and Landais, P. Hepatitis C virus type 1b(II) infection in France and Italy. Ann. Intern. Med. 122:161–168, 1995.

    Google Scholar 

  20. Davis, G. L., and Lau, J. Y. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology. 26(suppl):122S–127S, 1997.

    Article  Google Scholar 

  21. Kuo, G., Choo, Q. L., Alter, H. J., and Gitnick, G. L., An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 244:362–364, 1989

    Article  Google Scholar 

  22. Shiratori, S., Kato, N., Yokosuka, O., and Imazeki, F., Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology. 113:558–566, 1997.

    Article  Google Scholar 

  23. Poynard, T., Bedossa, P., Chevallier, M., and Mathurin, P., A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N. Engl. J. Med. 332:1457–1462, 1995.

    Article  Google Scholar 

  24. Lau, J. Y., Davis, G. L., Kniffen, J., and Qian, K. P., Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 341:1501–1504, 1993.

    Article  Google Scholar 

  25. Bishop, C., M., Neural Networks for Pattern Recognition, Oxford University Press, 1995.

  26. Takahashi, M., Saito, H., Higashimoto, M., Atsukawa, K., and Ishii, H. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J. Clin Microbiol. 43(1):186–191, 2005.

    Article  Google Scholar 

  27. Hwang, Y., Chen, E. Y., Gu, Z. J., Chuang, W. L., Yu, M. L., Lai, M. Y., Chao, Y. C., Lee, C. M., Wang, J. H., Dai, C. Y., Shian-Jy Bey, M., Liao, Y. T., Chen, P. J., and Chen, D. S. Genetic predisposition of responsiveness to therapy for chronic hepatitis C. Pharmacogenomics. 7(5):697–709, 2006.

    Article  Google Scholar 

  28. Kim, S, R., Hayashi, Y., Yoon, S., Taniguchi, M., Yang, M. K., Kim, K. I., Kim, M. M., Saeki, K., Nukata, I., and Imoto, S. Prediction of efficacy of interferon treatment of chronic hepatitis C by multivariate analysis and a new classification. Pathol Int. 48(3):215–220, 1998.

    Article  Google Scholar 

Download references

Acknowledgements

J.Y and A.S.N contributed equally to this study. The research of A.S.N is partially supported by a Grant-in-Aid for Private University High-Tech Research Center from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Author information

Authors and Affiliations

  1. Department of Medical Information and Management Science, Graduate School of Medicine, Nagoya University, 65, Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan

    Jun Yang, Kazunobu Yamauchi, Jiang Zheng, Kai Wang & Ken Kato

  2. School of Life System Science and Technology, Chukyo University, Chukyo, Japan

    Anto Satriyo Nugroho

  3. Hepato-Gastroenterology, School of Medicine, Fujita Health University, Fujita, Japan

    Kentaro Yoshioka

  4. Department of Computer Science and Engineering, Nagoya Institute of Technology, Nagoya, Japan

    Susumu Kuroyanagi & Akira Iwata

Authors
  1. Jun Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anto Satriyo Nugroho
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazunobu Yamauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kentaro Yoshioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiang Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kai Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ken Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Susumu Kuroyanagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Akira Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, J., Nugroho, A.S., Yamauchi, K. et al. Efficacy of Interferon Treatment for Chronic Hepatitis C Predicted by Feature Subset Selection and Support Vector Machine. J Med Syst 31, 117–123 (2007). https://doi.org/10.1007/s10916-006-9046-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10916-006-9046-8

Keywords

Search

Navigation